FDA Committee Recommends Formula for Fall COVID-19 Vaccines

FDA committee recommends formula for fall COVID-19 vaccines

An FDA committee on Thursday recommended that COVID-19 vaccines for the 2025-2026 respiratory virus season — which, for the first time, will be limited to certain groups — target the JN.1 lineage of SARS-CoV-2.

FDA gives Covid vaccine manufacturers instructions for next fall’s shot

The notice came shortly after an advisory panel meeting at which members debated the pros and cons of asking manufacturers to update their vaccines.

FDA panel recommends keeping COVID shots targeted to same strain as last year

The advisory committee, which met after the agency rolled out new vaccine guidelines, said companies should tailor their booster doses to the “JN.1” coronavirus lineage.

FDA Recommends 2025-2026 COVID-19 Vaccines Be Monovalent, Target LP.8.1 Strain

Following a meeting of the Vaccines and Related Biological Products Advisory Committee, the FDA announced their recommendation of COVID-19 vaccines targeting LP.8.1, a strain of the JN.1 variant that has become dominant in the US.

Uncertainty loomed as FDA advisors met to discuss this year’s COVID shot - WorldNL Magazine

Calling it a "practical question," he asked, "If we were to change strains, can we assume that age-specific licensure won't change for any of these [vaccine] products?" Currently, COVID-19 boosters are accessible to those aged 6 months and up. Weir reiterated that there was no answer. Another FDA official, David Kaslow, chimed in to say only, "Rest assured that we're engaging with the manufacturers on this topic." As a follow-up to that exchange…